|
市場調査レポート
商品コード
1687574
止血材製品の市場規模、シェア、成長分析：製品別、用途別、最終用途別、地域別 - 産業予測 2025～2032年Hemostasis Products Market Size, Share, and Growth Analysis, By Products (Topical Hemostasis, Infusible Hemostasis), By Application (Trauma, Surgery), By End Use, By Region - Industry Forecast 2025-2032 |
||||||
|
|||||||
| 止血材製品の市場規模、シェア、成長分析：製品別、用途別、最終用途別、地域別 - 産業予測 2025～2032年 |
|
出版日: 2025年03月17日
発行: SkyQuest
ページ情報: 英文 219 Pages
納期: 3～5営業日
|
- 全表示
- 概要
- 目次
止血材製品市場規模は2023年に16億9,000万米ドルと評価され、2024年の17億8,000万米ドルから2032年には27億4,000万米ドルに成長し、予測期間（2025-2032年）のCAGRは5.5%で成長する見通しです。
世界の止血材製品市場は、意識の高まりと医療技術の進歩に後押しされ、一貫した成長を遂げています。手術や外傷時の出血抑制、出血性疾患の管理に不可欠なこれらの製品に対する需要は、高齢化、慢性疾患や外科手術の増加によって高まっています。さらに、新興国市場におけるヘルスケアインフラの改善が市場拡大をさらに後押ししています。継続的な研究開発により、革新的でより安全かつ効率的な製品が登場しています。とはいえ、規制上のハードルやこれらの製品に関連する高コストが市場成長の課題となっています。こうした障害にもかかわらず、ヘルスケア基準や技術革新の進化に伴い、市場は継続的な発展を遂げようとしています。
目次
イントロダクション
- 調査の目的
- 調査範囲
- 定義
調査手法
- 情報調達
- 二次と一次データの方法
- 市場規模予測
- 市場の前提条件と制限
エグゼクティブサマリー
- 世界市場の見通し
- 供給と需要の動向分析
- セグメント別機会分析
市場力学と見通し
- 市場概要
- 市場規模
- 市場力学
- 促進要因と機会
- 抑制要因と課題
- ポーターの分析
主な市場の考察
- 重要成功要因
- 競合の程度
- 主な投資機会
- 市場エコシステム
- 市場の魅力指数（2024年）
- PESTEL分析
- マクロ経済指標
- バリューチェーン分析
- 価格分析
止血材製品市場規模：製品別& CAGR（2025-2032）
- 市場概要
- 局所止血
- コラーゲン
- 酸化再生セルロース
- ゼラチン
- 多糖類
- 輸液止血
- ドナー血液からの血小板濃縮物
- 血液由来FVIII
- 新鮮凍結血漿
- プロトロンビン複合体
- 高度な止血
- 流動性止血剤
- トロンビン
- フィブリン
- 合成シーラント
止血材製品市場規模：用途別& CAGR（2025-2032）
- 市場概要
- 外傷
- 手術
- 血友病
- 心筋梗塞
- 脳卒中
- 血栓症
止血材製品市場規模：最終用途別& CAGR（2025-2032）
- 市場概要
- 病院
- 外来手術センター
- その他
止血材製品市場規模：地域別& CAGR（2025-2032）
- 北米
- 米国
- カナダ
- 欧州
- ドイツ
- スペイン
- フランス
- 英国
- イタリア
- その他欧州地域
- アジア太平洋地域
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋地域
- ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
- 中東・アフリカ
- GCC諸国
- 南アフリカ
- その他中東・アフリカ
競合情報
- 上位5社の比較
- 主要企業の市場ポジショニング（2024年）
- 主な市場企業が採用した戦略
- 最近の市場動向
- 企業の市場シェア分析（2024年）
- 主要企業の企業プロファイル
- 企業の詳細
- 製品ポートフォリオ分析
- 企業のセグメント別シェア分析
- 収益の前年比比較（2022-2024）
主要企業プロファイル
- CSL Behring（Australia）
- Haemonetics Corporation（USA）
- Octapharma AG（Switzerland）
- Baxter International Inc.（USA）
- Johnson & Johnson（USA）
- Pfizer Inc.（USA）
- Becton, Dickinson and Company（USA）
- Medtronic plc（Ireland）
- Siemens Healthineers AG（Germany）
- Abbott Laboratories（USA）
- Roche Holding AG（Switzerland）
- Thermo Fisher Scientific Inc.（USA）
- Grifols, S.A.（Spain）
- Instrumentation Laboratory（Werfen）（USA）
- Stago Group（France）
- Sysmex Corporation（Japan）
- Siemens Healthineers AG（Germany）
- Danaher Corporation（USA）
- LivaNova PLC（UK）
- CryoLife, Inc.（USA）
結論と提言
Hemostasis Products Market size was valued at USD 1.69 billion in 2023 and is poised to grow from USD 1.78 billion in 2024 to USD 2.74 billion by 2032, growing at a CAGR of 5.5% during the forecast period (2025-2032).
The global hemostasis products market is experiencing consistent growth, fueled by heightened awareness and medical technology advancements. Essential for controlling bleeding during surgeries, trauma, and managing bleeding disorders, the demand for these products is amplified by an aging population and an increase in chronic diseases and surgical procedures. Additionally, improvements in healthcare infrastructure in developing regions are further propelling market expansion. Ongoing research and development are introducing innovative, safer, and more efficient hemostasis products. Nevertheless, regulatory hurdles and the high costs associated with these products present challenges to market growth. Despite these obstacles, the market is set for continued progress as healthcare standards and technological innovations evolve.
Top-down and bottom-up approaches were used to estimate and validate the size of the Hemostasis Products market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Hemostasis Products Market Segments Analysis
Global Hemostasis Products Market is segmented by Products, Application, End Use and region. Based on Products, the market is segmented into Topical Hemostasis, Infusible Hemostasis and Advanced Hemostasis. Based on Application, the market is segmented into Trauma, Surgery, Hemophilia, Myocardial Infarction, Stroke and Thrombosis. Based on End Use, the market is segmented into Hospitals, Ambulatory Surgical Centers and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Hemostasis Products Market
The Hemostasis Products market is significantly driven by innovations that focus on the development of safer and more environmentally friendly hemostatic solutions, including advanced agents and devices. These advancements not only enhance the management of bleeding complications and surgical processes but also contribute to better patient outcomes. As these improved products gain traction, they are stimulating growth within the market, leading to increased demand for effective hemostatic solutions. The ongoing emphasis on safety and effectiveness in hemostasis products plays a crucial role in shaping the future of medical practices related to bleeding control and surgical interventions.
Restraints in the Hemostasis Products Market
A significant challenge in the hemostasis products market is the high cost of these items. The elevated prices can limit accessibility for healthcare facilities with constrained budgets, as well as for patients in various regions. This financial barrier may impede the widespread adoption of advanced hemostasis solutions, ultimately restricting their market penetration. As a result, the impact on patient care could be substantial, as many healthcare providers may struggle to incorporate these critical products into their treatment protocols due to budgetary constraints, leading to disparities in the quality of care available to patients.
Market Trends of the Hemostasis Products Market
The Hemostasis Products market is witnessing a notable trend toward minimally invasive techniques, driven by a collective demand from healthcare providers and patients for less invasive solutions to manage bleeding during surgical procedures. This shift is propelling the development of advanced hemostasis products that minimize tissue damage, streamline recovery times, and enhance overall patient outcomes. As these techniques gain popularity, they offer increased patient comfort and shorter hospital stays, aligning perfectly with the healthcare industry's broader focus on value-based care. Consequently, manufacturers are innovating rapidly to meet these evolving needs, making the market poised for substantial growth.
Table of Contents
Introduction
- Objectives of the Study
- Scope of the Report
- Definitions
Research Methodology
- Information Procurement
- Secondary & Primary Data Methods
- Market Size Estimation
- Market Assumptions & Limitations
Executive Summary
- Global Market Outlook
- Supply & Demand Trend Analysis
- Segmental Opportunity Analysis
Market Dynamics & Outlook
- Market Overview
- Market Size
- Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
- Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers
Key Market Insights
- Key Success Factors
- Degree of Competition
- Top Investment Pockets
- Market Ecosystem
- Market Attractiveness Index, 2024
- PESTEL Analysis
- Macro-Economic Indicators
- Value Chain Analysis
- Pricing Analysis
Global Hemostasis Products Market Size by Products & CAGR (2025-2032)
- Market Overview
- Topical Hemostasis
- Collagen
- Oxidized Regenerated Cellulose
- Gelatin
- Polysaccharide
- Infusible Hemostasis
- Platelet Concentrates from Donor Blood
- FVIII Derived from Blood
- Fresh Frozen Plasma
- Prothrombin Complex
- Advanced Hemostasis
- Flowable
- Thrombin
- Fibrin
- Synthetic Sealants
Global Hemostasis Products Market Size by Application & CAGR (2025-2032)
- Market Overview
- Trauma
- Surgery
- Hemophilia
- Myocardial Infarction
- Stroke
- Thrombosis
Global Hemostasis Products Market Size by End Use & CAGR (2025-2032)
- Market Overview
- Hospitals
- Ambulatory Surgical Centers
- Others
Global Hemostasis Products Market Size & CAGR (2025-2032)
- North America (Products, Application, End Use)
- US
- Canada
- Europe (Products, Application, End Use)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Products, Application, End Use)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Products, Application, End Use)
- Brazil
- Rest of Latin America
- Middle East & Africa (Products, Application, End Use)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2024
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2024
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)
Key Company Profiles
- CSL Behring (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Haemonetics Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Octapharma AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Baxter International Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Johnson & Johnson (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Becton, Dickinson and Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Medtronic plc (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Siemens Healthineers AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Abbott Laboratories (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Roche Holding AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Thermo Fisher Scientific Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Grifols, S.A. (Spain)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Instrumentation Laboratory (Werfen) (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Stago Group (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sysmex Corporation (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Siemens Healthineers AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Danaher Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- LivaNova PLC (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- CryoLife, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Conclusion & Recommendations
